目的:探讨替米沙坦联合胺碘酮对高血压伴阵发性心房颤动患者血清脑钠肽(BNP)、基质金属蛋白酶-2(MMP-2)及结缔组织生长因子(CTGF)水平的影响。方法:90例高血压伴阵发性心房颤动患者随机分为胺碘酮+替米沙坦组和胺碘酮组,每组45例。胺碘酮组给予胺碘酮片维持治疗,胺碘酮+替米沙坦组给予替米沙坦联合胺碘酮治疗。治疗12个月后比较两组临床疗效及患者血压、心率、左心房容积、房颤次数及持续时间的变化,分析两组患者治疗前后血清BNP、MMP-2及CTGF水平变化。结果:胺碘酮+替米沙坦组治疗总有效率为95.6%,显著高于胺碘酮组的75.6%(P<0.05)。治疗后胺碘酮+替米沙坦组患者血压水平、左心房舒张末和收缩末容积心房颤动次数及维持时间均较前明显改善(P<0.05),且均明显优于胺碘酮组(P<0.05)。治疗后两组患者血清MMP-2、CTGF水平均较前明显降低(P<0.05),胺碘酮+替米沙坦组BNP、MMP-2及CTGF水平均明显低于胺碘酮组(P<0.05)。结论:替米沙坦联合胺碘酮治疗高血压伴阵发性心房颤动的疗效确切,能够抑制患者左心房扩大,减少心房颤动次数及持续时间,降低患者血清BNP、MMP-2及CTGF水平。 Objective: To investigate the effect of telmisartan and amiodarone on the levels of serum brain natriuretic peptide (BNP), matrix metalloproteinase-2 (MMP-2) and connective tissue growth factor (CTGF) in patients with hypertension and paroxysmal atrial fibrillation . Methods: 90 patients with hypertension complicated with paroxysmal atrial fibrillation were randomly divided into amiodarone + telmisartan group and amiodarone group, 45 cases in each group. Amiodarone group was given amiodarone tablets maintenance treatment, amiodarone + telmisartan group was given telmisartan combined with amiodarone treatment. Twelve months after treatment, the clinical efficacy, blood pressure, heart rate, left atrial volume, frequency and duration of atrial fibrillation in both groups were compared. The changes of serum BNP, MMP-2 and CTGF levels in both groups before and after treatment were analyzed. Results: The total effective rate of amiodarone + telmisartan group was 95.6%, which was significantly higher than that of amiodarone group (75.6%, P <0.05). After treatment, the levels of atrial fibrillation, the number of atrial fibrillation and the duration of left atrial end-diastolic and end-systolic volumes in amiodarone + telmisartan group were significantly improved (P <0.05), and were significantly better than those in amiodarone group P <0.05). After treatment, the levels of serum MMP-2 and CTGF in both groups were significantly lower than those before (P <0.05), and the levels of BNP, MMP-2 and CTGF in amiodarone + telmisartan group were significantly lower than those in amiodarone group <0.05). Conclusion: Telmisartan combined with amiodarone in the treatment of hypertension with paroxysmal atrial fibrillation is effective and can inhibit the patient’s left atrium enlargement, reduce the number and duration of atrial fibrillation and reduce serum BNP, MMP-2 and CTGF levels.